{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:41:44Z","timestamp":1780926104259,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s13555-022-00842-7","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T08:08:46Z","timestamp":1668845326000},"page":"221-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03661138","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Norito","family":"Katoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Ohya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimitoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza M.","family":"Raymundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-3556","authenticated-orcid":false,"given":"Henrique D.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"842_CR1","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et\u00a0al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397:2151\u201368.","journal-title":"Lancet"},{"key":"842_CR2","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et\u00a0al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397:2169\u201381.","journal-title":"Lancet"},{"key":"842_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21:21\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"842_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","volume":"122","author":"PM Brunner","year":"2019","unstructured":"Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122:449\u201355.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"842_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/exd.13514","volume":"27","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27:340\u201357.","journal-title":"Exp Dermatol"},{"key":"842_CR6","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.jaip.2020.02.022","volume":"8","author":"T Nomura","year":"2020","unstructured":"Nomura T, Wu J, Kabashima K, Guttman-Yassky E. Endophenotypic variations of atopic dermatitis by age, race, and ethnicity. J Allergy Clin Immunol Pract. 2020;8:1840\u201352.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"842_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/pai.13335","volume":"32","author":"NHA Suaini","year":"2021","unstructured":"Suaini NHA, Tan CPT, Loo EXL, Tham EH. Global differences in atopic dermatitis. Pediatr Allergy Immunol. 2021;32:23\u201333.","journal-title":"Pediatr Allergy Immunol"},{"key":"842_CR8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.alit.2020.02.006","volume":"69","author":"N Katoh","year":"2020","unstructured":"Katoh N, Ohya Y, Ikeda M, et\u00a0al. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020;69:356\u201369.","journal-title":"Allergol Int"},{"key":"842_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et\u00a0al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.","journal-title":"BMC Rheumatol"},{"key":"842_CR10","doi-asserted-by":"crossref","first-page":"S1015","DOI":"10.1002\/acr.21944","volume":"65","author":"J Voss","year":"2013","unstructured":"Voss J, Graff C, Schwartz A, et\u00a0al. Pharmacodynamics of a novel Jak1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects. Arthritis Rheum. 2013;65:S1015.","journal-title":"Arthritis Rheum"},{"key":"842_CR11","unstructured":"Rinvoq\u00ae Tablets [package insert]. AbbVie GK, August 2021. Accessed 7 Nov 2022. https:\/\/www.drugfuture.com\/pmda\/label\/rx\/112130_3999048G2024_1_10."},{"key":"842_CR12","unstructured":"Rinvoq\u00ae [package insert]. AbbVie, Inc., January 2022. Accessed 1 Feb 2022. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf."},{"key":"842_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdin.2021.11.001","volume":"6","author":"N Katoh","year":"2022","unstructured":"Katoh N, Ohya Y, Murota H, et\u00a0al. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): an interim 24-week analysis. JAAD Int. 2022;6:27\u201336.","journal-title":"JAAD Int"},{"key":"842_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jamadermatol.2022.1906","volume":"158","author":"R Elsawi","year":"2022","unstructured":"Elsawi R, Dainty K, Smith Begolka W et\u00a0al. The multidimensional burden of atopic dermatitis among adults: results from a large national survey. JAMA Dermatol. 2022;158:887\u2013892.","journal-title":"JAMA Dermatol"},{"key":"842_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.det.2017.02.003","volume":"35","author":"K Abuabara","year":"2017","unstructured":"Abuabara K, Margolis DJ, Langan SM. The long-term course of atopic dermatitis. Dermatol Clin. 2017;35:291\u20137.","journal-title":"Dermatol Clin"},{"key":"842_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jamadermatol.2013.10271","volume":"150","author":"JS Margolis","year":"2014","unstructured":"Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol. 2014;150:593\u2013600.","journal-title":"JAMA Dermatol"},{"key":"842_CR17","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","volume":"5","author":"M Boguniewicz","year":"2017","unstructured":"Boguniewicz M, Alexis AF, Beck LA, et\u00a0al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5:1519\u201331.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"842_CR18","unstructured":"Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et\u00a0al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of three phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022:S0190-9622(0122)00996-00993"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00842-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00842-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00842-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T18:31:25Z","timestamp":1673029885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00842-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00842-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"20 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}